Next report date
Report period
H1 2024
EPS estimate
—
Revenue estimate
—
0.800EUR
176.29 MEUR
2.67 BEUR
157.69 M
About HIKMA PHARMACEUTICALS ORD GBP0.10
Sector
CEO
Riad Mishlawi
Headquarters
London
Website
Employees (FY)
9.1 K
Founded
1978
FIGI
BBG000KRDK62
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.
Is this Hikma's cue for a break out?Will Hikma break out after a 5 year H&S pattern,
now that it's making progress in the Covid-19 vaccine business?
Hikma Pharmaceuticals - Injecting some bullish momentum.Buy Hikma Pharmaceuticals (HIK.L)
Hikma Pharmaceuticals PLC develops, manufactures, and markets pharmaceutical products. The Company offers branded and non-branded generic and in-licensed pharmaceutical products. Hikma Pharmaceuticals serves customers worldwide.
Market Cap: £4.79Billion
The lo
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange HIKMA PHARMACEUTICALS PLC stocks are traded under the ticker H5P.
HIKMA PHARMACEUTICALS PLC is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
H5P earnings for the last quarter are 1.17 EUR per share, whereas the estimation was 0.87 EUR resulting in a 34.63% surprise. The estimated earnings for the next quarter are 0.87 EUR per share. See more details about HIKMA PHARMACEUTICALS PLC earnings.
HIKMA PHARMACEUTICALS PLC revenue for the last quarter amounts to 1.31 B EUR despite the estimated figure of 1.22 B EUR. In the next quarter revenue is expected to reach 1.24 B EUR.
Yes, you can track HIKMA PHARMACEUTICALS PLC financials in yearly and quarterly reports right on TradingView.
H5P net income for the last quarter is 54.31 M EUR, while the quarter before that showed 123.62 M EUR of net income which accounts for −56.07% change. Track more HIKMA PHARMACEUTICALS PLC financial stats to get the full picture.
HIKMA PHARMACEUTICALS PLC dividend yield was 3.17% in 2023, and payout ratio reached 81.97%. The year before the numbers were 2.92% and 66.56% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, H5P shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HIKMA PHARMACEUTICALS PLC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 9.10 K employees. See our rating of the largest employees — is HIKMA PHARMACEUTICALS PLC on this list?
We've gathered analysts' opinions on HIKMA PHARMACEUTICALS PLC future price: according to them, H5P price has a max estimate of 32.92 EUR and a min estimate of 21.89 EUR. Read a more detailed HIKMA PHARMACEUTICALS PLC forecast: see what analysts think of HIKMA PHARMACEUTICALS PLC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HIKMA PHARMACEUTICALS PLC EBITDA is 618.68 M EUR, and current EBITDA margin is 23.72%. See more stats in HIKMA PHARMACEUTICALS PLC financial statements.